Growth hormone effects on hypertrophic scar formation: a randomized controlled trial of 62 burned children.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Scar scales were used to evaluate scar-severity at discharge, 6, 9, 12, and 18-24 months after burn, by three observers blinded to treatment.

Why It Was Studied

Computer-assisted planimetry allowed quantification of percentage of hypertrophic scar formation.

Types I and III collagens were localized and quantified in scars and normal skin of patients from both groups, using immunohistochemistry with confocal laser microscopy analysis.

Who Took Part

According to the abstract, 62 patients were involved.

The age groups tagged for this paper are children, both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

Insulin-like growth factor-1 blood levels helped assess compliance.

The subject headings attached to it are Burns, Cicatrix, Hypertrophic, Collagen, Fibrosis, Growth Hormone, Immunohistochemistry and Skin.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 62 patients.

The publication is from 2004 (Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.